Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations

Author(s):: Burke, G.; Hiscock, A.; Klein, A.; Niks, E.H. (0000-0001-5892-5143); Main, M.; Manzur, A.Y.; Ng, J.; Vile, C. de; Muntoni, F.; Beeson, D.; Robb, S.

Published: 2013
Publication type: Article / Letter to editor

Congenital myastheniaSalbutamolDOK7

Date issued: 2013-02-28
Language: English
Is part of: Neuromuscular Disorders (2013), Vol. 23, no. 2, p. 170-175
hdl: 1887/100817
doi: 10.1016/j.nmd.2012.11.004